Abstract Refractory lupus nephritis (LN), particularly mixed class IV + V histology, is the most treatment-resistant subtype. Rituximab (RTX) often results in incomplete B-cell depletion and limited efficacy in refractory patients, whereas CAR-T-cell therapy is associated with substantial risks of lymphodepletion. Here, we report a novel, off-the-shelf immunotherapy combining genetically enhanced allogeneic trifunctional NK cells with RTX without lymphodepleting preconditioning.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Minhua
Contact Minhua, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack